Background: Currently VEGF based and angiogenegis targeted therapies for lung cancer is an option of choice for late stage NSCLC. However, patients' response to the therapies is not equal, the question beyond this pheneomenon is that if the patients genetics background is associated to treatment outcome. Objective: To set-up a molecular diagnostic protocol for genotyping VEGF SNPs RS833061, RS302S039 and RS1S70360. Subject and method: Allelic variants of VEGF was acquired allele specific kinetics PCR and confirmed by sequencing using Sanger technology. Result and conclusion: Sequencing had confirmed the accuracy of the novel established novel VEGF allelic screening assay and for the first time, distribution of VGFR allelic variants amongst Vietnamese NSCLC was reported.